What was wrong and might now go right with clinical trials for lupus?

Current Rheumatology Reports

Volumn 11, Issue 4, 2009, Pages 235-237

  Merrill, Joan T ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RITUXIMAB; STEROID;

CLINICAL TRIAL; DISEASE ACTIVITY; DRUG RESPONSE; EXPERIMENTAL THERAPY; EXPLORATORY RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; INFERTILITY; LOW DRUG DOSE; NOTE; OBESITY; OFF LABEL DRUG USE; ORGAN INJURY; OUTCOME ASSESSMENT; PATIENT CARE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70449625253     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0044-y     Document Type: Note

References (10)

1. Human Genome Sciences: Human Genome Sciences and GlaxoSmithKline announce positive phase 3 study results for benlysta. Available at http://www.hgsi.com/ latest/human-genome-sciences-and-glaxosmithkline-announce-positive-phase-3- study-results-for-benl.html. Accessed July 20, 2009.
2. ClinicalTrials.gov: A study of belimumab in subjects with systemic lupus erythematosus (NCT00424476). Available at http://www.clinicaltrials.gov/ct2/ show/NCT00424476?term=belimumab&rank=2. Accessed July 20, 2009.
3. G. Grondal I. Gunnarsson J. Ronnelid, et al. 2000 Cytokine production, serum levels and disease activity in systemic lupus erythematosus Clin Exp Rheumatol 18 565 570 11072595 1:STN:280:DC%2BD3crhsVKktg%3D%3D
4. T.F. Liu B.M. Jones 1998 Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes Cytokine 10 140 147 9512904 10.1006/cyto.1997.0268 (Pubitemid 28077713)
5. W. Stohl 2002 B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases Curr Rheumatol Rep 4 345 350 12126587 10.1007/s11926-002-0044-7
6. J.T. Merrill R. Burgos-Vargas R. Westhovens, et al. 2009 Activity of abatacept in SLE: results of a 12-month phase II exploratory study [abstract OP-0009] Ann Rheum Dis 68 Suppl3 70
7. J.T. Merrill J.P. Buyon R. Furie, et al. 2009 Assessment of flares in lupus (SLE) patients in a placebo-controlled randomized phase II/III study of rituximab (explorer) [abstract OP-0010] Ann Rheum Dis 68 Suppl3 71
8. M. Petri K. Hobbs C. Gordon, et al. 2008 Randomized controlled trials (RTCs) of epratuzumab (anti-CD22 Mab Targeting B-Cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares [abstract OP-0016] Ann Rheum Dis 67 Suppl2 53
9. Merrill JT, Neuwelt CM, Wallace DJ, et al.: Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER [abstract L12]. Arthritis Rheum 2008, 58(Suppl 9).
10. Merrill J, Burgos-Vargas R, Westhovens, et al.: The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study [abstract L15]. Arthritis Rheum 2008, 58(Suppl 9).